Prodrug Information
| Prodrug General Information | Top | |||||
|---|---|---|---|---|---|---|
| Prodrug ID |
DBU89H
|
|||||
| Prodrug Name |
PMID8101355-Compound-4
|
|||||
| Indication | Kaposi sarcoma [ICD-11: 2B57; ICD-9: 176] | Investigative | [1] | |||
| Activation |
Prodrug 
|
|
Parent Drug 
|
|||
| 2D MOL | 2D MOL | |||||
| Prodrug Strategy |
Classical prodrug strategy
[Carrier linked prodrug]
|
|||||
| Improved property |
Increase solubility
|
[1] | ||||
| Description |
The water solubility of PMID8101355-Compound-4 is 0.35 mg/ml compared to that of taxol is less than 0.10 mg/ml.
|
[1] | ||||
| Parent Drug General Information | Top | |||||
|---|---|---|---|---|---|---|
| Parent Drug ID |
DC7ZW5
|
|||||
| Parent Drug Name |
Paclitaxel
|
|||||
| Synonyms |
TAXOL; 33069-62-4; Taxol A; Abraxane; Yewtaxan; Paxene; Genaxol; Paxceed; Plaxicel; Onxol; ABI-007; Ebetaxel; Genetaxyl; Capxol; Intaxel; LipoPac; OncoGel; Paclitaxel (Taxol); Genexol; Pacliex; TaxAlbin; Zisu; NSC-125973; EmPAC; Onxal; ABI 007; BMS 181339-01; UNII-P88XT4IS4D; MBT 0206; NSC125973; HSDB 6839; DHP 107; DRG-0190; MFCD00869953; NK 105; QW 8184; P88XT4IS4D; BMS-181339-01; nab-paclitaxel; NSC 125973; NCGC00164367-01; Cyclopax; Padexol; Anzatax; Cynviloq; Nanoxel; Sindaxel; Xorane; Cypher select; Coroflex Please; (NAB)-Paclitaxel; SMR000857385; EndoTAG 1; EndoTAG-1; LEP-ETU; SR-01000075350; Abraxane I.V. Suspension; Infinnium; Nanotaxel; Paclical; Pacligel; Paxoral; Paclitaxel/; CCRIS 8143; taxol derivatives; Genexol-PM; Paclitaxel,(S); Paclitaxel [USAN:USP:INN:BAN]; Abraxane (TN); Nanoparticle albumin bound paclitaxel; CAS-33069-62-4; IG 001; BMS-181339; Paclitaxel-SSMM-VIP; Liposome-entrapped paclitaxel easy-to-use; P-SSMM-VIP; TAXOL (TN); SCHEMBL3976; Nova-12005; Paclitaxel, Taxus brevifolia; Paclitaxel (JAN/USP/INN); MLS002154218; MLS002695976; OAS-PAC-100; BPBio1_000320; GTPL2770; Taxol (TN) (Bristol Meyers); DTXSID9023413; ACon1_002231; ANX-513; DHP-107; DHP-208; DTS-301; SDP-013; ACT02709; HY-B0015; MPI-5018; ABP000252; BDBM50001839; NSC745099; ZINC96006020; AKOS007930675; AKOS015969673; AKOS025312303; ACN-032459; CCG-220155; CS-1145; DB01229; GS-6554; NSC-745099; QW-8184; NCI60_000601; AB0069184; AB00513812; N1361; D00491; M-8858; M02242; N88686
Click to Show/Hide
|
|||||
| Formula |
C47H51NO14
|
|||||
| Canonical SMILES |
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
|
|||||
| InChI |
1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
|
|||||
| InChIKey |
RCINICONZNJXQF-MZXODVADSA-N
|
|||||
| CAS Number |
CAS 33069-62-4
|
|||||
| PubChem Compound ID | ||||||
| ChEBI ID |
CHEBI:45863
|
|||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Design, synthesis and biological activity of protaxols. Nature. 1993 Jul 29;364(6436):464-6. | |||||
| REF 2 | Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer. 2009 Jul 3;8:43. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.